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Introduction and Methodology
The American College of Cardiology (ACC)/American Heart
Association (AHA) Task Force on Practice Guidelines regu-
larly reviews existing guidelines to determine when an update
or full revision is needed. This process gives priority to areas
where major changes in text, particularly recommendations,
are mentioned on the basis of new understanding of evidence.
Minor changes in verbiage and references are discouraged.
The ACC/AHA Guidelines for Coronary Artery Bypass Graft
Surgery published in 1999 have now been updated. The
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ACC/AHA Guideline Update
full-text guidelines incorporating the updated material are
available on the Internet (www.acc.org or www.american-
heart.org) in both a version that shows the changes from the
1999 guidelines in track changes mode, with strike-through
indicating deleted text and underlining indicating new text,
and a “clean” version that fully incorporates the changes. This
article describes the major areas of change reflected in the
update in a format that we hope can be read and understood
as a stand-alone document. Please note we have changed the
table of contents headings in the 1999 guidelines from roman
numerals to unique identifying numbers. Interested readers
are referred to the full-length Internet version to completely
understand the context of these changes.
Classification of Recommendations and Level of Evidence
are expressed in the ACC/AHA format as follows:
Classification of Recommendations
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is useful and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the useful-
ness/efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is
not useful/effective and in some cases may be
harmful.
Level of Evidence
Level of Evidence A: Data are derived from multiple ran-
domized clinical trials or
meta-analyses.
Level of Evidence B: Data are derived from a single ran-
domized trial, or nonrandomized
studies.
Level of Evidence C: Only consensus opinion of experts,
case studies, or standard of care.
(Please refer to Table 1 in the full-text guidelines for more
details.)
Modification I
3.1.3. Morbidity Associated With CABG: Adverse
Cerebral Outcomes
4.1.1.1.1. Aortic Atherosclerosis and Macroembolic
Stroke
New material was added on off-pump coronary artery bypass
(OPCAB) and its role in neurological outcomes after CABG.
The material is reproduced below:
OPCAB avoids both aortic cannulation and cardiopulmo-
nary bypass. Accordingly, one would expect postoperative
neurological deficits to be reduced in patients undergoing
OPCAB. Three randomized controlled trials (1–3) have not
firmly established a significant change in neurological out-
comes between OPCAB patients and conventional CABG
patients. Each trial demonstrates problems inherent with
small patient cohorts, differing definitions, and patient selec-
tion. At this point, there is insufficient evidence of a differ-
ence in neurological outcomes for patients undergoing OP-
CAB compared with those undergoing conventional CABG
(4).
Modification II
3.3.2.2. Long-Term Outcome
New material was added with clinical trial data comparing
stents with CABG in patients with multivessel disease. Table
11 was revised to incorporate stent trial data and outcomes at
longer follow-up. The new text appears below:
Comparison with stents
Since the previous update of these guidelines, several trials
comparing stents with CABG in patients with multivessel
disease have been initiated. The Arterial Revascularization
Therapies Study Group (ARTS) trial enrolled 1205 patients
with multivessel coronary disease in whom a cardiac surgeon
and interventional cardiologist agreed that they could achieve
a similar extent of revascularization. In this randomized
comparison, there was no difference at 1 year in the combined
rate of death, myocardial infarction (MI), and stroke between
the 2 revascularization strategies (5). However, repeat revas-
cularization rates were higher with stenting (16.8% versus
3.5% with surgery), with a net cost savings of $2973 per
patient favoring the stent approach. In patients with diabetes
(n equals 198), the difference in repeat revascularization rates
was even more disparate (22.3% with stents versus 3.1% with
CABG), although overall event-free survival was similar (6)
(Table 11).
Similar results were reported by the Stent or Surgery (SoS)
trial investigators. The trial randomized 988 patients with
multivessel disease (57% 2-vessel; 42% 3-vessel) to revas-
cularization with percutaneous coronary intervention (PCI)
(78% received stents) or CABG (81% with pedicled left
internal mammary artery [IMA] graft). The primary end point
of repeat revascularization occurred in 21% of PCI patients
versus 6% of CABG patients at a median follow-up of 2 years
(hazard ratio equals 3.85, P less than 0.0001). Freedom from
angina was also better with surgery (79% versus 66%).
Mortality was higher in the PCI group but was influenced by
a particularly low surgical mortality and a high rate of
noncardiovascular death in the PCI group (7).
In the Angina With Extremely Serious Operative Mortality
Evaluation (AWESOME) study, 454 patients at 16 VA
hospitals with high-risk features for adverse outcome with
surgery were randomized to either surgery or PCI. High-risk
characteristics included prior open-heart surgery, age greater
than 70 years, ejection fraction less than 0.35, MI within 7
days, and the need for an intra-aortic balloon pump (IABP).
Stents were used in 54% of PCI patients. Survival was similar
(79% with CABG and 80% with PCI) at 36 months (8).
Finally, in the Stenting versus Internal Mammary Artery
(SIMA) trial, 121 patients with isolated proximal left anterior
descending coronary artery disease were randomly treated
with stenting or CABG (using the IMA). At 2.4 years of
follow-up, there were no differences in the rates of death, MI,
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TABLE 11. CABG vs PCI: Randomized Controlled Trials
Acute Outcome, % Late Outcome, %
Trial (Ref)
Age, y (%
Female) CAD N
Death:
CABG
PCI
QW-MI:
CABG
PCI
Hosp
CABG Death QW-MI Angina
RR, %
(Total/PCI/CABG)
Primary End
Point
Primary
End
Point, % F/U, y
PTCA trials
BARI (18) 61 (26%) MV 1829 1.3 4.6 N/A 15.6¶ 19.6 N/A 8/7/1 D 15.6¶ 8§
1.1 2.1 6.3 19.1¶ 21.3 N/A 54/34/31 19.1¶
EAST (19) 61 (26%) MV 392 1 10.3 N/A 17 19.6 12 13/13/1 DMIT 27.3 8
1 3.0† 10.1 21 16.6 20† 54/41/22 28.8
GABI (20) N/A (20%) MV 359 2.5 8 N/A 6.5 9.4 26 6/5/1 A 26 1
1.1 2.3† 8.5 2.6 4.5 29 44/27/21 29
Toulouse (21) 67 (23%) MV 152 1.3 6.6 N/A 10.5 1.3 5.3 9/9/0 A 5.2 5
1.3 3.9 3.9 13.2 5.3 21.1† 29/15/15 21.1†
RITA (22) 57 (19%) SVMV* 1011 1.2 2.4 N/A 3.6 5.2 21.5 4/3/1 DMI 8.6 2.5‡
0.8 3.5 4.5 3.1 6.7 31.3† 31/18/19 9.8
ERACI (23) 58 (13%) MV 127 4.6 6.2 N/A 4.7 7.8 3.2 6/3/3 DMIARR 23 3
1.5 6.3 1.5 9.5 7.8 4.8 37/14/22 53†
MASS (24) 56 (42%) SV (LAD) 142 1.4 1.4 N/A N/A N/A 2 0/0/0 DMIRR 3 3
1.4 0 11 N/A N/A 18 22/29/14 24†
Lausanne (25) 56 (20%) SV (LAD) 134 0 0 N/A 1.5 1.5 5 3/3/0 DMIRR 7.6 2‡
0 0 2.9 0 2.9 6 25/12/13 36.8†
CABRI (26) 60 (22%) MV 1054 1.3 N/A N/A 2.7 3.5 10.1 9/6/1 D 2.7 1
1.3 N/A N/A 3.9 4.9 13.9† 36/21/18 3.9
Stent trials
SoS (7) 61 (21%) MV 988 N/A N/A N/A 2 8 21 6/4/1 RR 6 1
5† 5 34† 21†/13/9 21†
ERACI II (16) 62 (21%) MV 450 N/A N/A N/A 8 6 8 5/0/0 DMICVARR 19 1.6
3† 3† 15† 17†/0/5 23
ARTS (5) 61 (24%) MV 1205 N/A N/A N/A 3 5 10 4/3/1 DMICVARR 12 1
3 6 21† 21†/16/7 26†
AWESOME (8) 67 (N/A) MV 454 N/A N/A N/A N/A N/A N/A N/A D 21 3
20
SIMA (9) 59 (21%) SV 121 N/A N/A N/A 4 4 5 0/0/0 DMIRR 7 2.4
2 5 9 24†/13/6 31†
LEIPZIG (17) 62 (25%) SV 220 N/A N/A N/A 2 5 21 8/8/0 DMIRR 15 0.5
0 3 38† 29/25/4 31†
CABG indicates coronary artery bypass graft; PCI, percutaneous coronary intervention; CAD, coronary artery disease; QW, Q wave; MI, myocardial infarction; Hosp
CABG, required CABG after PCI and before hospital discharge; RR, repeated revascularization; F/U, follow-up; BARI, Bypass Angioplasty Revascularization Investigation;
EAST, Emory Angioplasty Surgery Trial; GABI, German Angioplasty Bypass-surgery Investigation; RITA, Randomized Intervention Treatment of Angina; ERACI, Estudio
Randomizado Argentino de Angioplastia vs Cirugia; MASS, Medicine, Angioplasty, or Surgery Study; CABRI, Coronary Angioplasty versus Bypass Revascularization
Investigation; SoS, the Stent or Surgery trial; ERACI II, Coronary Angioplasty with Stenting vs Coronary Artery Bypass in patients with MV disease; ARTS, Arterial
Revascularization Therapies Study; AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; SIMA, Stenting vs Internal Mammary Artery; LEIPZIG,
Stenting vs Minimally Invasive Bypass Surgery; MV, multivessel; D, death; N/A, data not available; T, thallium defect; A, angina; SV, single vessel; and LAD, left anterior
descending coronary artery.
*Included total occlusion.
†P is less than 0.05 comparing CABG and PCI cohorts.
‡Planned 5-year follow-up (interim results).
§Primary end point and mortality at 8 years, other end points at 5 years.
Primary end point and mortality at 8 years, other end points at 3 years.
¶Statistically significant.
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functional class, medications, or quality of life. Repeat
revascularization was required more often (31% versus 7%)
in the stent group (9). Overall, 6 trials have now been
published comparing CABG with PCI utilizing stents in
single or multivessel disease. Compared with the earlier trials
utilizing balloon angioplasty, stent usage and left IMA
revascularization rates have increased (16–26). The results in
terms of death, MI, and stroke are similar in the more recent
trials; however, the disparity in the need for repeat revascu-
larization, which favors surgery, has narrowed (Table 11).
Modification III
4.1.2.4. Cardiac Biomarker Elevation and
Outcome
This section was added to reflect current understanding of the
prognostic value of cardiac biomarkers when assessed after
CABG.
Modification IV
4.2.3. Hormonal Manipulation
Although more than 30 observational studies showed a
reduced mortality for coronary disease in postmenopausal
women taking hormone therapy, hormone replacement is no
longer recommended for women undergoing CABG surgery.
The new material can be found in the full-text guidelines.
Modification V
5.7. Reoperation
The section on reoperation was rewritten to include emerging
understanding of the nature and sequelae of late vein graft
atherosclerosis. In patients in whom late vein graft stenosis is
found in vein grafts supplying the LAD coronary artery,
reoperation should be strongly considered to improve sur-
vival. The need for reoperation may be reduced as surgeons
increasingly utilize arterial conduits for the primary revas-
cularization. Please see the full-text guidelines for new
material.
Modification VI
5.11. CABG in Acute Coronary Syndromes
New text was added regarding the risk of CABG in acute
coronary syndrome patients treated with new and more
potent antithrombotic and antiplatelet therapies. This update
reflects more recent nomenclature that defines the spectrum
of acute coronary syndromes from unstable angina to non–
ST-segment elevation MI to ST-segment elevation MI. Where
appropriate, the writing committee used the new classifica-
tion in the document, recognizing, however, that many of the
cited trials categorized the patient subgroups according to
the older nomenclature. The new text is reproduced below.
A new issue that has arisen concerns the risk of CABG in
patients with acute coronary syndrome treated with new and
more potent antithrombotic and antiplatelet therapies. Several
studies have demonstrated a greater risk for postoperative
hemorrhage in patients treated with low-molecular-weight
heparin (10,10a,10b), abciximab (11), and clopidogrel (12). It
is important to understand the pharmacokinetics of these
agents to reduce the risk. For instance, no increased bleeding
was observed when the short-acting glycoprotein IIb/IIIa
inhibitor eptifibatide was discontinued at least 2 hours before
bypass (13), when platelet transfusions were appropriately
administered after abciximab (14), and when clopidogrel was
withheld for 5 days before surgery (12). In some instances,
the need for surgery supersedes the risk.
Modification VII
6.1. Less-Invasive CABG
The section on less-invasive CABG was extensively rewritten
to highlight advances in OPCAB with more recent clinical
trial data. Please refer to the full-text guidelines for further
details.
Modification VIII
6.1.1. Robotics
This new section was added to address the current under-
standing of robotic coronary bypass.
Modification IX
6.2. Arterial and Alternate Conduits
The Arterial and Alternate Conduits section was updated to
include more recent trial data and explore the use of multiple
IMA grafts (bilateral IMA, or BIMA).
Modification X
6.4. Transmyocardial Revascularization
This section was updated to include new prospective, con-
trolled, randomized trials that demonstrate efficacy of
transmyocardial revascularization (TMR) in select patients.
Modification XI
7.3. Hospital Environment
A new section on “Hospital Environment” was added to
explain the process of clinical care surrounding CABG
surgery and how appropriate implementation of clinical
guidelines can show measurable improvement in outcomes.
Modification XII
The section “Areas in Need of Future Research” was
eliminated because the material was covered in previous
sections.
Modification XIII
All of the recommendations in the CABG guideline update
were written in full sentences that express a complete
thought, such that a recommendation, even if separated and
presented apart from the rest of the document, would still
convey the full intent of the recommendation. It is hoped that
this will increase readers’ comprehension of the guidelines.
In the 1999 update, the committee did not rank the available
scientific evidence in an A, B, or C fashion. The level of
evidence for each recommendation is now provided. The
rewritten recommendations appear under their respective
headings below.
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3.1.2. Predicting Hospital Mortality
Class IIa
1. It is reasonable to use statistical risk models to
obtain objective estimates of CABG operative mor-
tality. (Level of Evidence: C)
3.1.3. Morbidity Associated With CABG: Adverse
Cerebral Outcomes
Class I
1. Significant atherosclerosis of the ascending aorta
mandates a surgical approach that will minimize the
possibility of arteriosclerotic emboli. (Level of Evi-
dence: C)
4.1.1.1.2. Atrial Fibrillation and Postoperative
Stroke
Class IIa
1. In post-CABG atrial fibrillation that is recurrent or
persists more than 24 hours, warfarin anticoagula-
tion for 4 weeks is probably indicated. (Level of
Evidence: C)
4.1.1.1.3. Recent Anterior MI, LV Mural
Thrombus, and Stroke Risk
Class IIa
1. Long-term (3 to 6 months) anticoagulation is prob-
ably indicated for the patient with recent anteroapi-
cal infarct and persistent wall-motion abnormality
after coronary bypass. (Level of Evidence: C)
Class IIb
1. In patients having recent anterior MI, preoperative
screening with echocardiography may be considered
to detect left ventricular (LV) thrombus, because the
technical approach and timing of surgery may be
altered. (Level of Evidence: C)
4.1.1.1.6. Carotid Disease and Neurological Risk
Reduction
Class IIa
1. Carotid endarterectomy is probably recommended
before CABG or concomitant to CABG in patients
with a symptomatic carotid stenosis or in asymptom-
atic patients with a unilateral or bilateral internal
carotid stenosis of 80% or more. (Level of Evidence: C)
2. Carotid screening is probably indicated in the fol-
lowing subsets: age greater than 65 years, left main
coronary stenosis, peripheral vascular disease, his-
tory of smoking, history of transient ischemic attack
or stroke, or carotid bruit on examination. (Level of
Evidence: C)
4.1.2.2. Myocardial Protection for Acutely
Depressed Cardiac Function
Class I
1. Blood cardioplegia should be considered in patients
undergoing cardiopulmonary bypass accompanying
urgent/emergency CABG for acute MI or unstable
angina. (Level of Evidence: B)
4.1.2.3. Protection for Chronically Dysfunctional
Myocardium
Class IIa
1. Blood cardioplegia is probably indicated in patients
undergoing cardiopulmonary bypass accompanying
CABG in the presence of a chronically dysfunctional
left ventricle. (Level of Evidence: B)
4.1.2.4. Cardiac Biomarker Elevation and
Outcome
Class IIb
1. Assessment of cardiac biomarkers in the first 24
hours after CABG may be considered. Patients with
the highest elevations of creatine kinase-MB (greater
than 5 times upper limits of normal) are at increased
risk of subsequent events. (Level of Evidence: B)
4.1.2.5. Adjuncts to Myocardial Protection
Class IIa
1. The use of a prophylactic intra-aortic balloon pump
(IABP) as an adjunct to myocardial protection is
probably indicated in patients with evidence of
ongoing myocardial ischemia and/or patients with a
subnormal cardiac index. (Level of Evidence: B)
4.1.2.7. Inferior Infarct with Right Ventricular
Involvement
Class IIa
1. After infarction that leads to clinically significant
right ventricular dysfunction, it is reasonable to
delay surgery for 4 weeks to allow recovery. (Level of
Evidence: C)
4.1.4. Reducing the Risk of Perioperative Infection
Class I
1. Preoperative antibiotic administration should be
used in all patients to reduce the risk of postopera-
tive infection. (Level of Evidence: A)
2. In the absence of complicating circumstances, a deep
sternal wound infection should be treated with ag-
gressive surgical debridement and early revascular-
ized muscle flap coverage. (Level of Evidence: B)
Class IIa
1. The risk for deep sternal wound infection is reduced
by aggressive control of perioperative hyperglyce-
mia with a continuous, intravenous insulin infusion
(15). (Level of Evidence: B)
4.1.5. Prevention of Postoperative Arrhythmias
Class I
1. Preoperative or early postoperative administration
of beta-blockers in patients without contraindica-
tions should be used as the standard therapy to
reduce the incidence and/or clinical sequelae of
atrial fibrillation after coronary bypass surgery.
(Level of Evidence: B)
Class IIa
1. Preoperative administration of amiodarone reduces
the incidence of postcardiotomy atrial fibrillation
and is an appropriate prophylactic therapy for
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patients at high risk for postoperative atrial fibril-
lation who have contraindications to therapy with
beta-blockers. (Level of Evidence: B)
2. Digoxin and nondihydropyridine calcium channel
blockers are useful for control of ventricular rate
but at present have no indication for prophylactic
use. (Level of Evidence: B)
Class IIb
1. Low-dose sotalol can be considered to reduce the
incidence of atrial fibrillation after CABG in pa-
tients who are not candidates for traditional beta-
blockers. (Level of Evidence: B)
4.2.1. Antiplatelet Therapy for SVG Patency
Class I
1. Aspirin is the drug of choice for prophylaxis against
early saphenous vein graft (SVG) closure. It is the
standard of care and should be continued indefi-
nitely given its benefit in preventing subsequent
clinical events. (Level of Evidence: A)
4.2.2. Pharmacological Management of
Hyperlipidemia
Class I
1. All CABG surgery patients should receive statin
therapy unless otherwise contraindicated. (Level of
Evidence: A)
4.2.3. Hormonal Manipulation
Class III
1. Initiation of hormone therapy is not recommended
for women undergoing CABG surgery. (Level of
Evidence: B)
4.2.4. Smoking Cessation
Class I
1. All smokers should receive educational counseling
and be offered smoking cessation therapy after
CABG. (Level of Evidence: B)
2. Pharmacological therapy including nicotine replace-
ment and bupropion (in select patients) should be
offered to patients indicating a willingness to quit.
(Level of Evidence: B)
4.2.5. Cardiac Rehabilitation
Class I
1. Cardiac rehabilitation should be offered to all eligi-
ble patients after CABG. (Level of Evidence: B)
5.6. Valve Disease
Class I
1. Patients undergoing CABG who have severe aortic
stenosis (mean gradient greater than or equal to
50 mm Hg or Doppler velocity greater than or equal
to 4 meters per second) who meet the criteria for
valve replacement should have concomitant aortic
valve replacement. (Level of Evidence: B)
Class IIa
1. For a preoperative diagnosis of clinically significant
mitral regurgitation concomitant mitral correction
at the time of CABG is probably indicated. (Level of
Evidence: B)
2. In patients undergoing CABG who have moderate
aortic stenosis and are at acceptable risk for aortic
valve replacement (mean gradient 30 to 50 mm Hg
or Doppler velocity 3 to 4 meters per second),
concomitant aortic valve replacement is probably
indicated. (Level of Evidence: B)
Class IIb
1. Patients undergoing CABG who have mild aortic
stenosis (mean gradient less than 30 mm Hg or
Doppler velocity less than 3 meters per second) may
be considered candidates for aortic valve replace-
ment if the risk of the combined procedure is
acceptable. (Level of Evidence: C)
5.11. CABG in Acute Coronary Syndromes
Class I
1. If clinical circumstances permit, clopidogrel should
be withheld for 5 days before the performance of
CABG surgery. (Level of Evidence: B)
6.2. Arterial and Alternate Conduits
Class I
1. In every patient undergoing CABG, the left IMA
should be given primary consideration for revascu-
larization of the LAD artery. (Level of Evidence: B)
6.4. Transmyocardial Revascularization (refer to
the TMR section of the Stable Angina Update)
Class IIa
1. Transmyocardial surgical laser revascularization,
either alone or in combination with coronary artery
bypass surgery, is reasonable in patients with angina
refractory to medical therapy who are not candi-
dates for PCI or surgical revascularization. (Level of
Evidence: A)
9.2.1. Asymptomatic or Mild Angina
Class I
1. CABG should be performed in patients with asymp-
tomatic ischemia or mild angina who have signifi-
cant left main coronary artery stenosis. (Level of
Evidence: A)
2. CABG should be performed in patients with asymp-
tomatic ischemia or mild angina who have left main
equivalent: significant (greater than or equal to
70%) stenosis of the proximal LAD and proximal
left circumflex artery. (Level of Evidence: A)
3. CABG is useful in patients with asymptomatic ische-
mia or mild angina who have 3-vessel disease. (Sur-
vival benefit is greater in patients with abnormal LV
function; eg, ejection fraction [EF] less than 0.50
and/or large areas of demonstrable myocardial is-
chemia.) (Level of Evidence: C)
Class IIa
1. CABG can be beneficial for patients with asymptom-
atic or mild angina who have proximal LAD stenosis
with 1- or 2-vessel disease. (This recommendation
becomes Class I if extensive ischemia is documented
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by a noninvasive study and/or LVEF is less than
0.50.) (Level of Evidence: A)
Class IIb
1. CABG may be considered for patients with asymp-
tomatic or mild angina who have 1- or 2-vessel
disease not involving the proximal LAD. (If a large
area of viable myocardium and high-risk criteria are
met on noninvasive testing, this recommendation
becomes a Class I.) (Level of Evidence: B)
9.2.2. Stable Angina
Class I
1. CABG is recommended for patients with stable
angina who have significant left main coronary
artery stenosis. (Level of Evidence: A)
2. CABG is recommended for patients with stable
angina who have left main equivalent: significant
(greater than or equal to 70%) stenosis of the
proximal LAD and proximal left circumflex artery.
(Level of Evidence: A)
3. CABG is recommended for patients with stable
angina who have 3-vessel disease. (Survival benefit is
greater when LVEF is less than 0.50.) (Level of
Evidence: A)
4. CABG is recommended in patients with stable an-
gina who have 2-vessel disease with significant prox-
imal LAD stenosis and either EF less than 0.50 or
demonstrable ischemia on noninvasive testing.
(Level of Evidence: A)
5. CABG is beneficial for patients with stable angina
who have 1- or 2-vessel CAD without significant
proximal LAD stenosis but with a large area of
viable myocardium and high-risk criteria on nonin-
vasive testing. (Level of Evidence: B)
6. CABG is beneficial for patients with stable angina
who have developed disabling angina despite maxi-
mal noninvasive therapy, when surgery can be per-
formed with acceptable risk. If the angina is not
typical, objective evidence of ischemia should be
obtained. (Level of Evidence: B)
Class IIa
1. CABG is reasonable in patients with stable angina who
have proximal LAD stenosis with 1-vessel disease.
(This recommendation becomes Class I if extensive
ischemia is documented by noninvasive study and/or
LVEF is less than 0.50.) (Level of Evidence: A)
2. CABG may be useful for patients with stable angina
who have 1- or 2-vessel CAD without significant
proximal LAD stenosis but who have a moderate
area of viable myocardium and demonstrable ische-
mia on noninvasive testing. (Level of Evidence: B)
Class III
1. CABG is not recommended for patients with stable
angina who have 1- or 2-vessel disease not involving
significant proximal LAD stenosis, patients who
have mild symptoms that are unlikely due to myo-
cardial ischemia, or patients who have not received
an adequate trial of medical therapy and the
following:
a. Have only a small area of viable myocardium
(Level of Evidence: B) or
b. Have no demonstrable ischemia on noninvasive
testing. (Level of Evidence: B)
2. CABG is not recommended for patients with stable
angina who have borderline coronary stenoses (50%
to 60% diameter in locations other than the left main
coronary artery) and no demonstrable ischemia on
noninvasive testing. (Level of Evidence: B)
3. CABG is not recommended for patients with stable
angina who have insignificant coronary stenosis (less
than 50% diameter reduction). (Level of Evidence: B)
9.2.3. Unstable Angina/Non–ST-Segment
Elevation MI
Class I
1. CABG should be performed for patients with unsta-
ble angina/non–ST-segment elevation MI with sig-
nificant left main coronary artery stenosis. (Level of
Evidence: A)
2. CABG should be performed for patients with unsta-
ble angina/non–ST-segment elevation MI who have
left main equivalent: significant (greater than or equal
to 70%) stenosis of the proximal LAD and proximal
left circumflex artery. (Level of Evidence: A)
3. CABG is recommended for unstable angina/non–
ST-segment elevation MI in patients in whom revas-
cularization is not optimal or possible and who have
ongoing ischemia not responsive to maximal nonsur-
gical therapy. (Level of Evidence: B)
Class IIa
1. CABG is probably indicated in patients with unsta-
ble angina/non–ST-segment elevation MI who have
proximal LAD stenosis with 1- or 2-vessel disease.
(Level of Evidence: A)
Class IIb
1. CABG may be considered for patients with unstable
angina/non–ST-segment elevation MI who have 1- or
2-vessel disease not involving the proximal LAD
when percutaneous revascularization is not optimal
or possible. (If there is a large area of viable
myocardium and high-risk criteria are met on non-
invasive testing, this recommendation becomes Class
I.) (Level of Evidence: B)
9.2.4. ST-Segment Elevation MI (STEMI)
Class I
1. Emergency or urgent CABG in patients with STEMI
should be undertaken in the following circumstances:
a. Failed angioplasty with persistent pain or hemody-
namic instability in patients with coronary anatomy
suitable for surgery. (Level of Evidence: B)
b. Persistent or recurrent ischemia refractory to med-
ical therapy in patients who have coronary anatomy
suitable for surgery, who have a significant area of
myocardium at risk, and who are not candidates for
PCI (Level of Evidence: B)
c. At the time of surgical repair of postinfarction
ventricular septal rupture or mitral valve insuffi-
ciency. (Level of Evidence: B)
d. Cardiogenic shock in patients less than 75 years old
with ST-segment elevation or left bundle-branch
block or posterior MI who develop shock within 36
hours of MI and are suitable for revascularization
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that can be performed within 18 hours of shock,
unless further support is futile because of the pa-
tient’s wishes or contraindications/unsuitability for
further invasive care. (Level of Evidence: A)
e. Life-threatening ventricular arrhythmias in the
presence of greater than or equal to 50% left main
stenosis and/or triple-vessel disease. (Level of Evi-
dence: B)
Class IIa
1. CABG may be performed as primary reperfusion in
patients who have suitable anatomy and who are not
candidates for or who have had failed fibrinolysis/
PCI and who are not in the early hours (6 to 12
hours) of evolving STEMI (Level of Evidence: B)
2. In patients who have had an ST-segment elevation
MI or non–ST-segment elevation MI, CABG mor-
tality is elevated for the first 3 to 7 days after
infarction, and the benefit of revascularization must
be balanced against this increased risk. Beyond 7
days after infarction, the criteria for revasculariza-
tion described in previous sections are applicable.
(Level of Evidence: B)
Class III
1. Emergency CABG should not be performed in pa-
tients with persistent angina and a small area of
myocardium at risk who are hemodynamically sta-
ble. (Level of Evidence: C)
2. Emergency CABG should not be performed in pa-
tients with successful epicardial reperfusion but
unsuccessful microvascular reperfusion. (Level of
Evidence: C)
9.2.5. Poor LV Function
Class I
1. CABG should be performed in patients with poor
LV function who have significant left main coronary
artery stenosis. (Level of Evidence: B)
2. CABG should be performed in patients with poor
LV function who have left main equivalent: signifi-
cant (greater than or equal to 70%) stenosis of the
proximal LAD and proximal left circumflex artery.
(Level of Evidence: B)
3. CABG should be performed in patients with poor
LV function who have proximal LAD stenosis with
2- or 3-vessel disease. (Level of Evidence: B)
Class IIa
1. CABG may be performed in patients with poor LV
function with significant viable noncontracting, re-
vascularizable myocardium and without any of the
above anatomic patterns. (Level of Evidence: B)
Class III
1. CABG should not be performed in patients with poor
LV function without evidence of intermittent ischemia
and without evidence of significant revascularizable
viable myocardium. (Level of Evidence: B)
9.2.6. Life-Threatening Ventricular Arrhythmias
Class I
1. CABG should be performed in patients with life-
threatening ventricular arrhythmias caused by left
main coronary artery stenosis. (Level of Evidence: B)
2. CABG should be performed in patients with life-
threatening ventricular arrhythmias caused by
3-vessel coronary disease. (Level of Evidence: B)
Class IIa
1. CABG is reasonable in bypassable 1- or 2-vessel
disease causing life-threatening ventricular arrhyth-
mias. (This becomes a Class I recommendation if the
arrhythmia is resuscitated sudden cardiac death or
sustained ventricular tachycardia.) (Level of Evi-
dence: B)
2. CABG is reasonable in life-threatening ventricular
arrhythmias caused by proximal LAD disease with
1- or 2-vessel disease. (This becomes a Class I
recommendation if the arrhythmia is resuscitated
sudden cardiac death or sustained ventricular
tachycardia.) (Level of Evidence: B)
Class III
1. CABG is not recommended in ventricular
tachycardia with scar and no evidence of ischemia.
(Level of Evidence: B)
9.2.7. CABG After Failed PTCA
Class I
1. CABG should be performed after failed percutane-
ous transluminal coronary angioplasty (PTCA) in
the presence of ongoing ischemia or threatened
occlusion with significant myocardium at risk. (Level
of Evidence: B)
2. CABG should be performed after failed PTCA for
hemodynamic compromise. (Level of Evidence: B)
Class IIa
1. CABG is reasonable after failed PTCA for a foreign
body in crucial anatomic position. (Level of Evi-
dence: C)
2. CABG can be beneficial after failed PTCA for
hemodynamic compromise in patients with impair-
ment of the coagulation system and without previous
sternotomy. (Level of Evidence: C)
Class IIb
1. CABG can be considered after failed PTCA for
hemodynamic compromise in patients with impair-
ment of the coagulation system and with previous
sternotomy. (Level of Evidence: C)
Class III
1. CABG is not recommended after failed PTCA in the
absence of ischemia. (Level of Evidence: C)
2. CABG is not recommended after failed PTCA with
inability to revascularize due to target anatomy or
no-reflow state. (Level of Evidence: C)
9.2.8. Patients With Previous CABG
Class I
1. Coronary bypass should be performed in patients
with prior CABG for disabling angina despite opti-
mal nonsurgical therapy. (If the angina is not typi-
cal, then objective evidence of ischemia should be
obtained.) (Level of Evidence: B)
2. Coronary bypass should be performed in patients
with prior CABG without patent bypass grafts but
with Class I indications for surgery for native-vessel
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coronary artery disease (significant left main coro-
nary stenosis, left main equivalent, 3-vessel disease).
(Level of Evidence: B)
Class IIa
1. Coronary bypass is reasonable in patients with prior
CABG and bypassable distal vessel(s) with a large
area of threatened myocardium by noninvasive stud-
ies. (Level of Evidence: B)
2. Coronary bypass is reasonable in patients with prior
CABG if atherosclerotic vein grafts with stenoses
greater than 50% supplying the LAD coronary
artery or large areas of myocardium are present.
(Level of Evidence: B)
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